Apologies for the highlighted text,
onCARlytics represents a paradigm shift in solid tumor treatment, it is our jewel in the crown
It has the potential to target and eradicate solid tumors that otherwise cannot be treated with approved CAR-T therapies alone.
onCARlytics is safe and has shown promise both in preclinical studies and early clinical trials, offering a novel approach for solid tumor therapy.
If successful, onCARlytics could open up 90% of the cancer market and allow CD19 therapies to become an option to treat patients with solid tumours (valued at USD$500B).
More importantly we are only six months away from learning early results from the OASIS combination trial with Amgen's Blincyto ... you just got to love the science and the unbelievable value proposition it represents
GLTAH - Go Team Imugene
.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1767 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 1177 | 1 |
View Market Depth
| Last trade - 09.19am 15/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable